DK1735308T3 - Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer - Google Patents
Kondenserede azadecalinringe som glucocorticoidreceptormodulatorerInfo
- Publication number
- DK1735308T3 DK1735308T3 DK05725295T DK05725295T DK1735308T3 DK 1735308 T3 DK1735308 T3 DK 1735308T3 DK 05725295 T DK05725295 T DK 05725295T DK 05725295 T DK05725295 T DK 05725295T DK 1735308 T3 DK1735308 T3 DK 1735308T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor modulators
- glucocorticoid receptor
- azadecaline
- condensed
- rings
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55183604P | 2004-03-09 | 2004-03-09 | |
PCT/US2005/008049 WO2005087769A1 (en) | 2004-03-09 | 2005-03-09 | Fused ring azadecalin glucocorticoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1735308T3 true DK1735308T3 (da) | 2009-01-19 |
Family
ID=34961932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05725295T DK1735308T3 (da) | 2004-03-09 | 2005-03-09 | Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer |
Country Status (18)
Country | Link |
---|---|
US (4) | US7928237B2 (da) |
EP (1) | EP1735308B1 (da) |
JP (1) | JP4931794B2 (da) |
KR (1) | KR101185281B1 (da) |
CN (1) | CN101027301B (da) |
AT (1) | ATE407934T1 (da) |
AU (1) | AU2005222421B2 (da) |
CA (1) | CA2558899C (da) |
CY (1) | CY1108621T1 (da) |
DE (1) | DE602005009687D1 (da) |
DK (1) | DK1735308T3 (da) |
ES (1) | ES2313317T3 (da) |
HK (1) | HK1104813A1 (da) |
IL (1) | IL177982A (da) |
NZ (1) | NZ550362A (da) |
PT (1) | PT1735308E (da) |
WO (1) | WO2005087769A1 (da) |
ZA (1) | ZA200608306B (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1735308T3 (da) * | 2004-03-09 | 2009-01-19 | Corcept Therapeutics Inc | Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer |
TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
WO2009050136A2 (en) * | 2007-10-17 | 2009-04-23 | Laboratoire Hra Pharma | Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome |
EP2364146B1 (en) * | 2008-11-07 | 2019-06-19 | University of Sheffield | Medicament and method of diagnosis |
CA2761255C (en) * | 2009-05-12 | 2017-05-09 | Corcept Therapeutics, Inc. | Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene |
WO2011053574A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
EP2524057B1 (en) * | 2010-01-15 | 2016-03-30 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
JP2013536250A (ja) * | 2010-08-27 | 2013-09-19 | コーセプト セラピューティクス, インコーポレイテッド | ピリジル−アミン縮合アザデカリンモジュレーター |
US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
US9006568B2 (en) * | 2012-02-15 | 2015-04-14 | Phillips 66 Company | Synthesis of photovoltaic conjugated polymers |
US20130225633A1 (en) * | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
KR102062640B1 (ko) * | 2012-05-25 | 2020-01-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합된 아자데칼린 글루코코르티코이드 수용체 조절제 |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
US9691986B2 (en) | 2012-12-03 | 2017-06-27 | Solarmer Energy, Inc. | Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells |
FI3848027T3 (fi) * | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
WO2015077537A1 (en) * | 2013-11-25 | 2015-05-28 | Corcept Therapeutics, Inc. | Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators |
CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
CA2978960C (en) | 2015-03-30 | 2023-05-02 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
WO2017027851A1 (en) | 2015-08-13 | 2017-02-16 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
US9905769B2 (en) | 2015-10-01 | 2018-02-27 | Phillips 66 Company | Process of manufacturing an electron transport material |
WO2017058406A1 (en) | 2015-10-01 | 2017-04-06 | Phillips 66 Company | Formation of films for organic photovoltaics |
US10418555B2 (en) | 2015-10-01 | 2019-09-17 | Phillips 66 Company | Formation of films for organic photovoltaics |
US10312448B2 (en) | 2015-10-01 | 2019-06-04 | Phillips 66 Company | Process of manufacturing an electron transport material |
US9911919B2 (en) | 2015-10-01 | 2018-03-06 | Phillips 66 Company | Process of manufacturing an electron transport material |
JP6765443B2 (ja) | 2016-01-19 | 2020-10-07 | コーセプト セラピューティクス, インコーポレイテッド | 異所性クッシング症候群の鑑別診断 |
CN109071537A (zh) | 2016-03-01 | 2018-12-21 | 科赛普特治疗学股份有限公司 | 用于加强检查点抑制剂的糖皮质激素受体调节剂的应用 |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
EP3592358A4 (en) | 2017-03-09 | 2020-12-16 | Corcept Therapeutics, Inc. | USE OF GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF CATECHOLAMIN SECRETING TUMORS |
KR102342620B1 (ko) | 2017-03-31 | 2021-12-22 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제 |
CA3065555A1 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
CA3121193C (en) | 2018-12-19 | 2024-03-12 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
EP3927345A4 (en) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | THERAPEUTIC USES OF RELACORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR DERIVED FROM AZADECALIN FUSED TO A HETEROARYL KETONE |
JP2022552422A (ja) | 2019-10-16 | 2022-12-15 | コーセプト セラピューティクス, インコーポレイテッド | 選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球/リンパ球比を正常化する方法 |
MX2022006633A (es) | 2019-12-11 | 2022-06-24 | Corcept Therapeutics Inc | Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. |
US20230358768A1 (en) | 2019-12-21 | 2023-11-09 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
IL294953A (en) * | 2020-02-10 | 2022-09-01 | Corcept Therapeutics Inc | Methods for inducing an antitumor response using a selective glucocorticoid receptor modulator |
MX2022016445A (es) | 2020-06-22 | 2023-02-01 | Corcept Therapeutics Inc | Antagonistas del receptor de glucocorticoides de indazol cuaternario. |
WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
CN116829556A (zh) * | 2021-02-03 | 2023-09-29 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
WO2024006773A1 (en) * | 2022-06-28 | 2024-01-04 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
JP4498602B2 (ja) * | 1998-03-10 | 2010-07-07 | リサーチ・トライアングル・インスティチュート | 新規なオピエート化合物、その調製法及び使用法 |
GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
WO2003061651A1 (en) * | 2002-01-22 | 2003-07-31 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
DK1735308T3 (da) * | 2004-03-09 | 2009-01-19 | Corcept Therapeutics Inc | Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer |
CA2761255C (en) * | 2009-05-12 | 2017-05-09 | Corcept Therapeutics, Inc. | Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene |
-
2005
- 2005-03-09 DK DK05725295T patent/DK1735308T3/da active
- 2005-03-09 PT PT05725295T patent/PT1735308E/pt unknown
- 2005-03-09 NZ NZ550362A patent/NZ550362A/en not_active IP Right Cessation
- 2005-03-09 CN CN2005800114815A patent/CN101027301B/zh active Active
- 2005-03-09 DE DE602005009687T patent/DE602005009687D1/de active Active
- 2005-03-09 WO PCT/US2005/008049 patent/WO2005087769A1/en active Application Filing
- 2005-03-09 AU AU2005222421A patent/AU2005222421B2/en active Active
- 2005-03-09 AT AT05725295T patent/ATE407934T1/de active
- 2005-03-09 US US10/591,884 patent/US7928237B2/en active Active
- 2005-03-09 ES ES05725295T patent/ES2313317T3/es active Active
- 2005-03-09 KR KR1020067020988A patent/KR101185281B1/ko active IP Right Grant
- 2005-03-09 CA CA2558899A patent/CA2558899C/en active Active
- 2005-03-09 EP EP05725295A patent/EP1735308B1/en active Active
- 2005-03-09 JP JP2007503030A patent/JP4931794B2/ja active Active
-
2006
- 2006-09-10 IL IL177982A patent/IL177982A/en active IP Right Grant
- 2006-10-05 ZA ZA200608306A patent/ZA200608306B/xx unknown
-
2007
- 2007-06-27 HK HK07106903.6A patent/HK1104813A1/xx unknown
-
2008
- 2008-12-05 CY CY20081101413T patent/CY1108621T1/el unknown
-
2011
- 2011-03-11 US US13/046,529 patent/US20110166110A1/en not_active Abandoned
-
2012
- 2012-05-21 US US13/476,776 patent/US8557839B2/en active Active
-
2013
- 2013-09-12 US US14/025,459 patent/US20140179671A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT1735308E (pt) | 2008-12-02 |
DE602005009687D1 (de) | 2008-10-23 |
AU2005222421A1 (en) | 2005-09-22 |
CN101027301A (zh) | 2007-08-29 |
IL177982A (en) | 2012-09-24 |
ZA200608306B (en) | 2009-02-25 |
KR20070029684A (ko) | 2007-03-14 |
CN101027301B (zh) | 2011-06-29 |
US7928237B2 (en) | 2011-04-19 |
CY1108621T1 (el) | 2014-04-09 |
EP1735308A1 (en) | 2006-12-27 |
NZ550362A (en) | 2010-06-25 |
US8557839B2 (en) | 2013-10-15 |
HK1104813A1 (en) | 2008-01-25 |
EP1735308B1 (en) | 2008-09-10 |
US20140179671A1 (en) | 2014-06-26 |
US20110166110A1 (en) | 2011-07-07 |
US20120225856A1 (en) | 2012-09-06 |
JP4931794B2 (ja) | 2012-05-16 |
ES2313317T3 (es) | 2009-03-01 |
WO2005087769A1 (en) | 2005-09-22 |
US20070281928A1 (en) | 2007-12-06 |
AU2005222421B2 (en) | 2010-09-23 |
CA2558899C (en) | 2013-02-05 |
ATE407934T1 (de) | 2008-09-15 |
KR101185281B1 (ko) | 2012-09-21 |
IL177982A0 (en) | 2006-12-31 |
CA2558899A1 (en) | 2005-09-22 |
JP2007528417A (ja) | 2007-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1735308T3 (da) | Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer | |
DK1761497T3 (da) | Azadecalinglucocorticoidreceptormodulatorer | |
ATE473744T1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren | |
DK1521733T3 (da) | Modulatorer af glucocorticoid receptoren | |
ATE497492T1 (de) | Reinigung von montelukast | |
DK2060570T3 (da) | Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater | |
TW200705255A (en) | Ring management | |
DK1833799T3 (da) | 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil | |
DK1633697T3 (da) | Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser | |
TNSN07196A1 (en) | Potentiators of glutamate receptors | |
DK1682530T3 (da) | Pyrrolsubstituerede indoler som inhibitorer af PAI-1 | |
DK1840125T3 (da) | Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater | |
CY1109963T1 (el) | Μεθοδος για την κατασκευη μιας φλαντζας συνδεσης | |
EA200601267A1 (ru) | Модуляторы рецепторов андрогена | |
DK1201655T3 (da) | Fremgangsmåde til fremstilling af non-steroide glucocorticoidreceptormodulatorer | |
DK1987357T3 (da) | Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf | |
BRPI0514672A (pt) | polipeptìdeos de fusobacterium e métodos de uso | |
DE502005003893D1 (de) | Ringfilter für ringförmige Nuten | |
DK1519936T3 (da) | Fremgangsmåde til fremstilling af nevirapin | |
TW200718704A (en) | Processes for the production of polycyclic fused ring compounds | |
EA200801402A1 (ru) | Карбаматные соединения в качестве агонистов рецептора 5-нт | |
CR11571A (es) | Derivaods de ftalazinona | |
AU320848S (en) | Diamond ring | |
SE0401606L (sv) | Klockring | |
CR20110590A (es) | Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil)3,3- dimetil-butiramida |